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lncRNA profile study reveals the 
mRNAs and lncRNAs associated 
with docetaxel resistance in breast 
cancer cells
Peide Huang1,3,4, Fengyu Li3, Lin Li3, Yuling You3, Shizhi Luo3, Zhensheng Dong3, Qiang Gao3, 
Song Wu2, Nils Brünner1 & Jan Stenvang1
Resistance to adjuvant systemic treatment, including taxanes (docetaxel and paclitaxel) is a major 
clinical problem for breast cancer patients. lncRNAs (long non-coding RNAs) are non-coding transcripts, 
which have recently emerged as important players in a variety of biological processes, including cancer 
development and chemotherapy resistance. However, the contribution of lncRNAs to docetaxel 
resistance in breast cancer and the relationship between lncRNAs and taxane-resistance genes are still 
unclear. Here, we performed comprehensive RNA sequencing and analyses on two docetaxel-resistant 
breast cancer cell lines (MCF7-RES and MDA-RES) and their docetaxel-sensitive parental cell lines. 
We identified protein coding genes and pathways that may contribute to docetaxel resistance. More 
importantly, we identified lncRNAs that were consistently up-regulated or down-regulated in both 
the MCF7-RES and MDA-RES cells. The co-expression network and location analyses pinpointed four 
overexpressed lncRNAs located within or near the ABCB1 (ATP-binding cassette subfamily B member 1) 
locus, which might up-regulate the expression of ABCB1. We also identified the lncRNA EPB41L4A-AS2 
(EPB41L4A Antisense RNA 2) as a potential biomarker for docetaxel sensitivity. These findings have 
improved our understanding of the mechanisms underlying docetaxel resistance in breast cancer and 
have provided potential biomarkers to predict the response to docetaxel in breast cancer patients.
Breast cancer is the most frequently diagnosed cancer among females and the leading cause of cancer death 
among women worldwide1. Multiple treatment modalities are used in breast cancer, such as surgery, radiation 
therapy, chemotherapy and target therapy. Taxanes, including docetaxel and paclitaxel, are among the most com-
monly used chemotherapeutic agents to treat breast cancer2. However, patients receiving a taxane treatment may 
become resistant to taxanes, thus resulting in recurrence and metastatic disease.
To reduce patient suffering from disease recurrence caused by taxane resistance, researchers focus on the 
molecular mechanisms and predictive biomarkers of taxane resistance at multiple levels. Several genes are asso-
ciated with taxane resistance. The differential expression of the ABCB1 gene is one of the most studied putative 
biomarkers in taxane-resistant cancers3,4. Pgp (permeability glycoprotein), encoded by the ABCB1 gene, has been 
reported to act as an ATP-dependent efflux pump and reduce taxane concentration by expelling the drug5. Other 
genes, such as ABCG2 (ATP binding cassette subfamily G member 2)6 ABCB4 (ATP binding cassette subfamily B 
member 4)7 are also involved in the process of taxane resistance. However, the underlying mechanism of taxane 
resistance in breast cancer is still not fully elucidated, and the regulators of the taxane-resistant genes remain 
unknown. As a result, there are presently no predictive biomarkers for taxanes in clinical use.
Long non-coding RNAs (lncRNAs) are defined as RNAs longer than 200 nucleotides, with little potential 
in protein coding. Many lncRNAs are described to influence mRNA generation and expression8. Recent stud-
ies have shown that lncRNAs are also implicated in chemotherapy resistance. The lncRNA HOTAIR (HOX 
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Transcript Antisense RNA) is reported to contribute to cisplatin resistance in human lung adenocarcinoma 
cells via down-regulating p21WAF1/CIP1 expression9. Another study found that the lncRNA MRUL (multidrug 
resistance related and up-regulated lncRNA) promotes ABCB1 expression in multidrug-resistant gastric can-
cer10. More recently, data have shown that two lncRNAs, ROR (regulator of reprogramming) and CCAT1 (colon 
cancer-associated transcript-1), regulate docetaxel resistance in lung adenocarcinoma11,12. Furthermore, from a 
transcriptome microarray study, the lncRNAs HIF1A-AS2 (HIF1A Antisense RNA 2) and AK124454 were shown 
to promote cell proliferation and invasion in TNBC (triple-negative breast cancers) cells and contribute to pacl-
itaxel resistance13. However, the contribution of lncRNAs to docetaxel resistance in breast cancer is still unclear.
In this study, we carried out whole transcriptome sequencing in two cell lines, MCF-7 and MDA-MB-231, 
and in their docetaxel-resistant sublines, MCF7-RES and MDA-RES. We identified significantly differentially 
expressed (SDE) mRNAs and lncRNAs between the parental and resistant sublines, and we also uncovered the 
potential relationship between the SDE mRNAs and lncRNAs. Compared with previous studies, we discovered 
several novel genes in addition to ABCB1 which might contribute to the taxane-resistant phenotype of breast 
cancers. More important, we identified a group of lncRNAs that might potentially regulate taxane sensitivity by 
controlling the expression of chemotherapy-resistant genes.
Results
Sequencing results and quality control. By performing Illumina-based RNA-Seq sequencing, a total 
of 1,825,984,984 raw reads were produced from the 12 RNA samples (3 independent samples from each cell line 
(Table 1)). After quality control, 1,750,124,272 clean reads (157.5 Gb) were obtained.
The proportion of clean reads among the raw reads of the 12 samples ranged from 94.32% to 96.95%. The 
proportion of clean reads with a Phred quality value greater than 30 among the samples ranged from 88.38% to 
92.96%. The GC (guanine and cytosine nucleotides) content of the clean reads of the 12 samples ranged from 
47.26% to 49.89%. In total, 82.94% to 91.33% of the clean reads were aligned against the human reference genome 
(Table 1).
Overview of mRNA expression and the significantly differentially expressed mRNAs between 
the parental and docetaxel-resistant cell groups. A total of 13,714 mRNAs were detected. More 
than 97.81% of the mRNAs was detected simultaneously among 3 passages of the same cell line (Sup Fig. 1A). 
The FPKM (fragments per kilobase million) values of the 13,714 mRNAs from 12 samples were centralized and 
normalized for the PCA (Principal component analysis). The results show that PC1 (Principal component 1) 
accounted for 52.28% of the total variance and could separate the MDA cells from the MCF7 cells; PC2 (Principal 
component 2) accounted for 13.91% of the total variance and separated the parental and docetaxel-resistant MDA 
cells. However, parental and docetaxel-resistant MCF7 cells clustered together (Sup Fig. 1B).
Differentially expressed mRNAs between the parental and docetaxel-resistant cell groups were calculated by 
DESeq in the two cell lines. The criteria of |Log2FC| > 1 (Log2 (fold change)), FDR < 0.1 (false discovery rate) 
was used to select the SDE mRNAs. We identified 1630 and 957 SDE mRNAs in the MDA-RES and MCF7-RES 
groups by comparing them to their parental groups, respectively, as shown in the volcano figure (Fig. 1A).
In the MDA-RES cells, 782 mRNAs were significantly up-regulated, and 848 mRNAs were significantly 
down-regulated. In the MCF7-RES cells, 627 mRNAs were significantly up-regulated, and 330 mRNAs were 
significantly down-regulated.
Sample MCF7_12_P MCF7_14_P MCF7_15_P MCF7_13_T MCF7_14_T MCF7_15_T MDA_13_P MDA_14_P MDA_16_P MDA_14_T MDA_15_T MDA_16_T
Number of 
raw reads 155,368,324 150,086,362 154,603,830 151,890,702 146,565,380 150,531,888 154,601,446 150,960,982 155,560,554 150,067,038 154,602,638 151,145,840
Raw data 




147,254,586 145,503,292 148,444,124 145,691,082 141,393,020 143,013,044 149,175,500 146,265,718 146,883,552 144,846,612 149,085,610 142,568,132
Clean data 




94.78 96.95 96.02 95.92 96.47 95.01 96.49 96.89 94.42 96.52 96.43 94.32
Q30 
reads(%) 88.66 92.75 89.63 89.73 92.72 88.81 90.36 92.57 89.23 92.96 90.54 88.38




126,241,357 129,177,823 134,000,511 133,059,665 125,613,559 122,233,249 133,556,825 129,562,173 126,202,348 128,884,515 132,119,668 118,246,009
Mapping 
rate(%) 85.73 88.78 90.27 91.33 88.84 85.47 89.53 88.58 85.92 88.98 88.62 82.94
Table 1. Summary of data yield and quality control. For the sample names, P represents the parental cells, T 
represents the docetaxel-resistant cells, number represents the passage.
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Figure 1. Overview of the mRNA expression and significantly differentially expressed mRNAs between 
the parental and docetaxel-resistant cell groups. (A) Volcano figure showing the significantly differentially 
expressed genes in the MDA-RES and MCF7-RES cells in comparison to their parental cells. The blue dots 
represent mRNAs with |Log2FC| > 1, FDR < 0.1. (B) Venn diagrams of the significantly up-regulated or down-
regulated mRNAs in both of the cells. (C) Complete-linkage clustering with the 124 consistent SDE mRNAs in 
the 12 samples. D. KEGG pathway enrichment and GO analysis for the consistent SDE genes. Left panel: GO 
functional classification of the consistent SDE genes. Red, green, and blue represent the three classes of the GO 
term. The top 10 enriched GO terms are shown in each class. Right panel: Scatter plot for the KEGG enrichment 
of the consistent SDE genes. RichFactor is the ratio of the consistent SDE genes annotated in a pathway to all 
the genes in this pathway. The Q value is the corrected p-value. The top 14 pathways with a Q value < 0.05 are 
shown in the figure.
www.nature.com/scientificreports/
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The most studied MDR (multidrug resistance) related gene, ABCB1 was dramatically up-regulated in both the 
MDA-RES and MCF7-RES cells (Fig. 1A), which was consistent with a previous report4. The top ten significantly 
up- or down-regulated genes in the MDA-RES or MCF7-RES cells are shown in Sup Table 1.
By analyzing the list of significantly up-regulated and down-regulated mRNAs in the MDA-RES and 
MCF7-RES cells, we found 80 mRNAs that were consistently up-regulated and 44 mRNAs that were consistently 
down-regulated in both of the cells (Fig. 1B, Sup Table 2).
Using these 124 consistent SDE mRNAs, the 12 samples were clustered into two groups (MDA-MB-231 and 
MCF-7) (Fig. 1C), which indicated that the mRNA diversity between the MCF-7 cells and MDA-MB-231 cells 
was greater than that between the docetaxel-resistant and parental cells.
GO (Gene ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses 
of the significantly differentially expressed genes. A KEGG pathway analysis was performed in each 
cell line. In the MCF7-RES cells, the three most enriched KEGG pathways associated with the SDE mRNAs were 
the metabolic pathways, axon guidance, and neuroactive ligand-receptor interaction. However, other pathways, 
such as the PI3K-Akt signaling pathway, Wnt signaling pathway, ECM-receptor interaction and ABC transport-
ers, were also significantly enriched (Sup Fig. 2).
In the MDA-RES cells, the PI3K-Akt signaling pathway, cytokine-cytokine receptor interaction, and pathways 
in cancer were the top three pathways, followed by the metabolic pathway, AGE-RAGE signaling pathway, and 
the cell adhesion molecules (CAMs) pathway. Furthermore, ABC transporters, the MAPK signaling pathway and 
ECM-receptor interaction were also significantly enriched (Sup Fig. 3).
We also performed the KEGG pathway analysis on the 124 consistent SDE mRNAs shared by the MCF7 and 
MDA cells. As shown in Fig. 1D, 14 signaling pathways were significantly enriched (Q value < 0.05). The most 
significantly enriched pathway was the cGMP-PKG signaling pathway. However, the ABC transporters, PI3K-Akt 
signaling pathway, AGE-RAGE signaling pathway in diabetic complications, and HIF-1 signaling pathway were 
also significantly enriched.
A GO analysis for the consistent SDE mRNAs was also performed to identify the function of the coding 
transcripts. With regard to biological processes, the most enriched GO term associated with the consistent SDE 
mRNAs was cellular process. With regard to the cellular component, the most enriched GO terms were cell and 
cell part. Moreover, the most enriched GO terms associated with the consistent SDE mRNAs for molecular func-
tion were binding and protein binding (Fig. 1D).
Overview of lncRNA expression and the significantly differentially expressed lncRNAs between 
the parental and docetaxel-resistant cell groups. NONCODE 2016 was used to annotate the lncR-
NAs. The lncRNAs were classified into 4 subgroups as antisense, exonic, linc (long intergenic non-coding), and 
sense no exonic lncRNAs, according to their location and their relationship with nearby genes. The classifica-
tion of the lncRNAs in the NONCODE database was provided online (http://www.noncode.org/datadownload/
NONCODE2016_human_cc.tgz). We found that lincRNAs and antisense lncRNAs were the two most abundant 
subtypes in all the cell lines (Fig. 2A).
A total of 39,363 lncRNAs were identified in the 12 RNA samples. More than 81.55% of the lncRNAs were 
detected simultaneously among three independent passages of the same cell line (Sup Fig. 3A). The differentially 
expressed lncRNAs between the parental and docetaxel-resistant cell groups were calculated by DESeq. We iden-
tified 2,150 and 815 SDE lncRNAs (|Log2FC| > 1, FDR < 0.1) in MDA-RES and MCF7-RES groups (Fig. 2B,C). 
The SDE lncRNAs identified in the MDA-RES cells included 415 antisense lncRNAs, 1179 intergenic lncRNAs, 
429 exonic lncRNAs and 127 sense no exonic lncRNAs. While in the MCF7-RES cells, the SDE lncRNAs included 
184 antisense lncRNAs, 435 intergenic lncRNAs, 161 exonic lncRNAs, and 35 sense no exonic lncRNAs (Fig. 2C).
By analyzing the list of SDE lncRNAs in the MCF7-RES and MDA-RES cells, we found 50 lncRNAs that 
were consistently up-regulated, while 22 lncRNAs were consistently down-regulated in both the MCF7-RES and 
MDA-RES cell lines (Fig. 2C, Sup Table 3).
By performing complete-linkage clustering with these consistent SDE lncRNAs, the 12 samples were clustered 
into two groups (parental and resistant) perfectly (Fig. 2D).
lncRNA-mRNA co-expression network construction and docetaxel-resistant module detec-
tion. It is well documented that lncRNAs function as regulators of target mRNAs8,14. Additionally, lncRNAs 
and their target mRNAs usually present similar expression patterns15–17. To predict the target mRNAs of the 
lncRNAs, we used the WGCNA (weighted gene co-expression network analysis)18 R software package to detect 
similar expression patterns between the SDE lncRNAs and mRNAs.
All the SDE genes (72 lncRNAs and 124 mRNAs) were subjected to the WGCNA analysis. We identified 4 
groups of co-expressed genes, termed ‘modules’ (Fig. 3A). Each module was labeled with a unique color under-
neath the cluster tree19.
Inside a given module, the expression profiles of the transcripts can be summarized by the ‘module eigengene’, 
which is the weighted average of the module gene expression profiles19. To identify the module associate with 
docetaxel-resistant status, we regressed each of the 4 module eigengenes on docetaxel-resistant status. We found 
that the Turquoise and Gray modules were most significantly associated with docetaxel-resistant status (Fig. 3B). 
Of these 2 associated modules, the Turquoise was positively correlated with docetaxel resistance, meaning that 
the genes in this module are predominantly up-regulated in docetaxel-resistant cells. In contrast, the Gray mod-
ule was negatively correlated with a docetaxel-resistant status, meaning that most genes in this module were 
down-regulated in the docetaxel-resistant cells.
www.nature.com/scientificreports/
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To identify the genes that are central and highly connected in the docetaxel-resistance-associated modules, we 
selected Hub genes with |GS| > 0.4 (gene significance) and |MM| > 0.8 (module membership) in the two modules 
and visualized these genes by Cytoscape (Fig. 3C).
In the Turquoise module, we identified 59 hub genes, including 40 protein coding genes and 19 lncRNAs 
(Sup Table 4). Several well-known chemotherapy-resistance-associated genes including ABCB1 were found in 
the protein coding genes list. We found that 39 genes, including 22 protein coding and 17 non-coding, were 
Figure 2. Overview of the lncRNA expression and significantly differentially expressed lncRNAs between 
the parental and docetaxel-resistant cell groups. (A) The subgroups and number of lncRNAs detected in the 
docetaxel-resistant and parental cell lines (P represents the parental cell line; T represents the docetaxel-
resistant cell line). (B) Volcano figure showing the significantly differentially expressed lncRNAs in the MDA-
RES and MCF7-RES cells compared to their parental cells. The blue dots represent lncRNAs with |Log2FC| > 1, 
FDR < 0.1. (C) Upper panel: Venn diagrams of consistently up-regulated or down-regulated lncRNAs in 
both of the MDA-RES and MCF7-RES cells. Lower panel: the bar chat shows the subgroups and numbers of 
significantly up-regulated or down-regulated lncRNAs. (D) Complete-linkage clustering with the 72 consistent 
SDE lncRNAs in the 12 samples.
www.nature.com/scientificreports/
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linked to ABCB1 (Table 2). Among the 22 coding genes linked to ABCB1, we found that many of the genes are 
implicated in drug or chemotherapy resistance, such as ABCB4, ADAM22 (disintegrin and metalloproteinase 
domain-containing protein 22), GPNMB (glycoprotein nmb), COL21A1 (collagen type XXI alpha 1 chain), and 
ITGB4 (integrin subunit beta 4) (Table 2, marked with asterisks). Strikingly, we found a list of lncRNAs closely 
Figure 3. lncRNA-mRNA co-expression network construction and docetaxel-resistant module detection 
using the consistent SDE mRNAs and lncRNAs. (A) A total of 72 SDE lncRNAs and 124 SDE mRNAs were 
subjected to the WGCNA analysis. Using the hierarchical clustering method, 4 groups of co-expressed genes, 
termed ‘modules’, were identified. (B) The 4 modules were related to the docetaxel-resistant status. The 
correlation coefficients representing the module-trait relationships are indicated in the center of the modules, 
and the corresponding P-values are in the brackets. (C) The hub genes in the Turquoise and Gray modules 
were visualized by Cytoscape. Pathway enrichment was performed with the hub genes in the two modules. a. 
The connections of the 59 hub genes in the Turquoise module. The white nodes represent the hub genes, and 
the red lines indicate the connections to ABCB1. b. The connections of the 29 hub genes in the Gray module. 
The white nodes represent the hub genes, and the red lines indicate the connections to NONHSAG041250.2 
(EPB41L4A-AS2).
www.nature.com/scientificreports/
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linked to ABCB1 in the Turquoise module (Table 2), indicating that these lncRNAs may function as regulators 
of ABCB1.
In the Gray module, we identified 29 hub genes, including 22 protein coding genes and 7 lncRNAs (Sup 
Table 5). We found that some of the protein coding genes are reported to be associated with chemotherapy sensi-
tivity. The over-expression of TSPYL5 (testis-specific Y-encoded-like protein 5) and TFAP2A (transcription factor 
AP-2 alpha) are reported to increase the cell sensitivity to chemotherapy in different cancers20–23. Moreover, in the 
Gray module, we also identified several lncRNAs that were consistently down-regulated in the docetaxel-resistant 
MCF7-RES and MDA-RES cells. Notably, an antisense lncRNA, EPB41L4A-AS2 (NONHSAG041250.2), which 
is reported to inhibit tumor proliferation and is associated with favorable prognoses in breast cancer24, was iden-
tified as a hub gene in this module.
Location and functional analysis of the important lncRNAs and mRNAs in the resistance- asso-
ciated modules. To uncover the relationship of the lncRNAs and the most studied MDR-related gene, 
ABCB1, we analyzed the genomic locations of the lncRNAs that were linked with ABCB1 in the Turquoise mod-
ule. Our results showed that several lncRNAs were localized at the regions overlapping or near the ABCB1 gene 
locus. The locations of lncRNAs NONHSAG048134.2, NONHSAG048135.2 and NONHSAG096479.1 overlapped 
with ABCB1. NONHSAG048135.2 was transcribed in the same direction and was localized to the exons of the 
Node links to ABCB1 Region Log2 (MCF-RES/MCF-7) MCF padj Log2 (MDA-RES/MDA-MB-231) MDA padj
ABCB4* chr7:87031361-87105019 4.391873563 3.0392E-81 4.798895486 1.78397E-10
ADAM22* chr7:87563566-87832204 3.031204518 5.24574E-71 2.042465751 8.48915E-17
C1orf226 chr1:162348696-162356608 1.30617006 2.08367E-08 1.218567139 0.002493763
CCL5 chr17:34198495-34207377 4.281358914 2.28917E-14 3.425308925 0.016192984
CNGB3 chr8:87586024-87755903 2.927154653 8.53446E-07 4.3137896 4.17421E-05
COL21A1* chr6:55921388-56112378 4.89902163 1.49237E-23 3.061434362 0.004363835
FAXDC2 chr5:154198052-154230213 1.236440283 7.16651E-08 2.057091728 0.002687024
GPNMB* chr7:23286316-23314729 3.634939682 3.41382E-06 3.979523007 5.07143E-21
GUCY1A2 chr11:106557910-106889171 3.923885806 3.04573E-08 2.419615258 0.008199061
ITGB4* chr17:73717516-73753899 1.264990464 3.44083E-05 1.28963119 1.4676E-10
MAP1A chr15:43809806-43823818 1.820284794 0.005866863 2.930015235 4.37426E-12
NEB chr2:152341853-152591001 5.071449042 1.95162E-15 1.272976565 0.074560694
NOS3 chr7:150688144-150711687 4.229375395 6.48733E-15 1.677234009 0.009459785
P2RX7 chr12:121570631-121624354 3.174388573 3.15828E-08 3.742594891 0.024211279
PALMD chr1:100111431-100160097 3.418917876 1.04212E-12 3.476080265 0.000185888
PCLO chr7:82383321-82792197 5.256273053 6.619E-18 1.320153124 0.000404159
PTHLH chr12:28111017-28124916 5.660286658 2.89989E-37 1.102001097 0.022862275
RORC chr1:151778547-151804348 2.438996823 2.19322E-10 2.525862773 0.011217021
RUNDC3B chr7:87257729-87461613 3.889364599 2.65512E-25 2.527876138 1.00736E-12
SEMA3E chr7:82993222-83278479 3.4028601 3.31146E-90 3.774037375 3.23296E-38
STK31 chr7:23749838-23872132 4.004572338 6.89337E-33 1.460119768 0.003048511
TBX20 chr7:35242042-35293711 3.537902823 0.000168179 3.453322279 0.025040493
NONHSAG002193.2 chr1:100111502-100152712 2.306183482 0.00000108 1.765770312 0.035443541
NONHSAG013923.2 chr13:89793303-89815434 2.858465834 4.82E-10 2.473788666 0.000298561
NONHSAG048134.2 chr7:87150777-87151726 4.661655972 4.16E-34 4.849823297 1.08E-20
NONHSAG048135.2 chr7:87229434-87342570 3.06347186 6.79E-13 3.485170506 3.16E-09
NONHSAG048143.2 chr7:87829109-87832202 3.266694083 3.73E-33 1.013242299 0.016081777
NONHSAG051078.2 chr8:115582746-115686229 3.00855 2.46E-23 1.929201108 0.008762611
NONHSAG067189.1 chr13:89594992-89616155 5.165615 7.06E-47 3.947107328 1.03E-13
NONHSAG067198.1 chr13:91322334-91371571 3.65213 2.43E-20 2.165973989 0.003256962
NONHSAG067199.1 chr13:91465148-91472109 4.027848 2.53E-24 2.187822303 0.000869085
NONHSAG085133.1 chr3:165592410-165780111 2.821382 1.38E-20 5.039315468 1.02E-23
NONHSAG085134.1 chr3:165609026-165630375 2.314128 1.26E-09 3.197328113 0.000000284
NONHSAG085135.1 chr3:165633442-165636497 2.229836 1.85E-09 3.518443205 9.92E-10
NONHSAG085136.1 chr3:165651727-165888351 1.995099 0.000138828 1.567863816 0.09203305
NONHSAG085734.1 chr3:126760621-126763555 1.264793 0.05765945 1.590391302 0.083859182
NONHSAG096192.1 chr7:23296654-23301401 2.382385 1.7E-09 3.160102464 2.15E-08
NONHSAG096479.1 chr7:87075330-87214789 7.059226 1.77E-99 7.209915426 7.23E-58
NONHSAG096480.1 chr7:87445537-87459755 2.385153266 9.27E-10 1.169846587 0.062398465
Table 2. Nodes links to ABCB1 in the Turquoise module. *Asterisk indicates the gene which has been 
implicated in chemotherapy resistant; padj refer to adjusted P value.
www.nature.com/scientificreports/
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ABCB1 gene, indicating that it was an exonic lncRNA, whereas NONHSAG048134.2 and NONHSAG096479.1 
were located in the antisense strand to the ABCB1 gene locus, indicating that these two lncRNAs were antisense 
lncRNAs for the gene ABCB1 (Fig. 4A). Another lncRNA, NONHSAG048143.2, was located 480 kb upstream of 
ABCB1 (Fig. 4A).
The correlation analysis of the expression data of these four lncRNAs and ABCB1 mRNA revealed a strong 
positive correlation between the expression of these lncRNAs and the ABCB1 gene (Fig. 4B), suggesting that there 
was regulatory relationship between these lncRNAs and the ABCB1 gene.
We downloaded the ChIP-seq (chromatin immunoprecipitation sequencing) datasets for MCF-7 and 
MDA-MB-231 breast cancer cells from the GEO (Gene expression omnibus) and ENCODE (encyclopedia of 
DNA elements) databases. By calculating the H3K4me1/H3K4me3 ratios at each TSS (transcriptional start site) of 
the lncRNAs near ABCB1, we found that the lncRNA NONHSAG048143.2, upstream of ABCB1, was associated 
with an enhancer-like chromatin state (H3K4me1/H3K4me3 ratio > 1.2) in both the MCF-7 and MDA-MB-231 
cells (Fig. 4C). This indicated that NONHSAG048143.2 might function as an eRNA (enhancer lncRNA)25 in the 
regulation of the ABCB1 gene.
We also identified a previously reported lncRNA, NR_024549 (termed MRUL)10, which located 400 kb down-
stream of ABCB1. This lncRNA was found to be down-regulated in MCF7-RES cells (Fig. 4D).
The other lncRNA, EPB41L4A-AS2, which had been reported to be a potential tumor suppressor and prog-
nostic biomarker was located head to head with the EPB41L4A gene in the antisense orientation (Fig. 5A). 
The correlation analysis on the expression data of this lncRNA and EPB41L4A and ABCB1 mRNAs revealed 
strong positive correlation between the expression of EPB41L4A-AS2 and EPB41L4A (Pearson correlation test, 
Figure 4. Location and functional analysis of important lncRNAs closely linked to ABCB1 mRNAs in the 
Turquoise module. (A) The location of MRUL, ABCB1 and the four lncRNAs near the ABCB1 locus. (B) 
Correlation between the expression of the 4 lncRNAs and the ABCB1 gene. (C) The H3K4me1/H3K4me3 status 
at the TSS region (indicated by the red box) of the lncRNA NONHSAG048143.2. (D) The MRUL expression 
(FPKM) in the docetaxel-resistant cells (red bars) and parental cells (blue bars).
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R = 0.892, P = 9.61 × 10−5, Fig. 5B) but strong negative correlation between the expression of EPB41L4A-AS2 and 
ABCB1 genes (Pearson correlation test, R = 0.774, P = 0.003, Fig. 5B).
To validate the relationship between EPB41L4A-AS2 expression and chemotherapy resistance, we down-
loaded the primary microarray data GSE21997, which profile the RNA expression in primary breast cancers 
before neoadjuvant chemotherapy (doxorubicin and docetaxel)26, from the GEO repository database. And 
the residual breast cancer burden (RCB) index was adopted to classified the breast cancer patients as previous 
report27. Patients of RCB-III class were considered to be therapeutic resistant. By analyzing the microarray data, 
we found that the expression of EPB41L4A-AS2 was significantly lower (Student’s t-test, P = 0.042, Fig. 5D) in the 
resistant group than the non-resistant group.
Real-time qPCR validation of important SDE lncRNAs and mRNAs. The qPCR results showed that 
the expression of the mRNAs, including ABCB1, ABCB4, ADAM22, COL21A1, GPNMB, and ITGB4 and the 
expressions of the lncRNAs, including NONHSAG096479.1, NONHSAG048134.2, NONHSAG048135.2, and 
Figure 5. Location and functional analysis of the lncRNA EPB41L4A-AS2. (A) The location of the 
EPB41L4A-AS2 and EPB41L4A genes. (B) Correlation between the expression of EPB41L4A-AS2 and 
EPB41L4A and ABCB1. (C) The expression of EPB41L4A-AS2 (FPKM) in the docetaxel-resistant cells (red 
bars) and parental cells (blue bars). (D) The expression of EPB41L4A-AS2 in clinical breast cancers tissues 
(GSE21997) before neoadjuvant chemotherapy (doxorubicin and docetaxel).
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NONHSAG048143.2 were up-regulated in docetaxel resistant MCF7-RES and MDA-RES cell lines compared to 
their parental cells lines. On the contrary, the expressions of the mRNAs EPB41L4A and TSPYL5 and the expres-
sions of the lncRNAs EPB41L4A-AS2 were down-regulated in docetaxel resistant MCF7-RES and MDA-RES 
cell lines compared to their parental cells lines (Fig. 6). The deregulated genes were identically regulated in both 
the MCF (Fig. 6A) and MDA (Fig. 6B) groups. Importantly, the qPCR analyses validated the results obtained by 
RNA-seq data.
Discussion
Taxanes are a class of anti-microtubule agents that have been demonstrated to be more efficient than 
anthracycline-based regimens and are listed as the first-line regimens for breast cancer28,29. However, patients 
receiving taxane treatment usually develop resistance to taxanes, thus resulting in recurrence and metastasis30.
To uncover the mechanisms underlying taxane resistance and find novel potential predictive biomarkers for 
clinical use, many studies have been carried out in both clinical cancer samples and resistant cell model sys-
tems4,31–38. Through this research, a number of genes were identified to be associated with taxane resistance, and 
the differential expression of the ABCB1 gene was extensively investigated and identified as one of the most cred-
ible biomarkers in chemotherapy-resistant cancers3,4,33,34,36,37. However, these previous studies were mainly based 
on microarray hybridization technologies, and therefore, limited concordant differentially expressed genes are 
shared between the different studies3,4,33,34,36,37, and the common denominator associated with taxane resistance 
remains largely unknown. Moreover, the underlying mechanism of taxane resistance in breast cancer and the 
regulators of taxane-resistant genes still needs to be uncovered.
lncRNAs regulate gene expression at the transcriptional and epigenetic levels39. Recent studies have shown 
that lncRNAs are also implicated in tumor chemotherapy resistance9–13. However, the contribution of lncRNAs to 
docetaxel resistance in breast cancer is still unclear.
Here, we used RNA-Seq technology (Illumina platform), which does not rely on pre-designed complement 
probes and shows a higher sensitivity in the detection of genes with very low expression and a higher accuracy 
in the detection of extremely abundant genes compared with microarray technology40, to gain a more compre-
hensive and global profile of mRNAs and lncRNAs in docetaxel-resistant breast cancer cells (MCF7-RES and 
MDA- RES).
We detected an average of 26,329 lncRNAs and 13,010 mRNAs per sample. Importantly, the lncRNAs and 
mRNAs showed a high consistency between different passages from the same cell subline (Sup Figs 1A, 4A), 
which was in concordance with the reports on the high reproductivity of Illumina RNA-Seq40 and demonstrated 
the reliability of these data.
Figure 6. Real-time qPCR validation of important SDE lncRNAs and mRNAs. Validation of the important 
SDE lncRNAs and mRNAs in the MCF cells (A) and MDA cells (B). The heights of the red columns represent 
the logarithmically transformed mean fold-changes between the resistant and parental cells detected by 
QPCR. Data from three duplications are presented as mean ± standard error. The blue columns represent the 
logarithmically transformed fold-changes between the resistant and parental groups detected by RNA-seq. 
‘Max’ represents an infinitely large number due to the absence of NONHSAG096479.1 in the parental cells.
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We identified 1630 and 957 SDE coding genes in the MDA-RES and MCF7-RES groups compared to their 
parental cells, respectively. In comparison to the previous microarray analysis research in the same cell lines4, we 
identified more consistently up-regulated or down-regulated genes shared by the MCF7-RES and MDA-RES cells 
(124 vs 16), which are the potential common denominators associated with taxane resistance. The KEGG pathway 
analyses were performed on the SDE genes in each cell line, which identified the common pathways shared by 
the two cell lines and found that the most enriched pathways were different between the two cell lines (Sup Figs 2, 
3). The 124 consistent SDE genes were also significantly enriched in 14 signaling pathways (Q-value < 0.05). The 
most significantly enriched pathway was the cGMP-PKG signaling pathway. However, the ABC transporters, the 
PI3K-Akt signaling pathway, and the AGE-RAGE signaling pathway in diabetic complications signaling pathway 
were also significantly enriched. Cyclic GMP (cGMP) is the intracellular second messenger that mediates the 
action of nitric oxide (NO) and natriuretic peptides (NPs), regulating a broad array of physiological processes. 
The role of this pathway in chemotherapy is unclear. However, it is implicated in the regulation of apoptosis in 
cancer cells41 and has been reported to mediate the inhibition of Pgp efflux function by YC-142. The PI3K-Akt 
signaling pathway was the most significantly enriched pathway in the MDA-MB-231 cells (Sup Fig. 3) and was 
also significantly enriched in the MCF-7 cells. Although it has not been reported in the previous taxane-resistance 
studies in breast cancer3,4,33,34,36,37, we found that it was linked to docetaxel resistance in prostate cancer43,44. These 
results indicated that in addition to the classical pathways, such as the ABC transporters and ECM-receptor inter-
action pathways, other signaling pathways may also play important roles in taxane resistance in breast cancer.
In addition to the mRNA analysis, the more novel and important work here was the profiling of the lncR-
NAs in the parental and docetaxel-resistant breast cancer cells. We identified 72 consistently SDE lncRNAs (50 
up-regulated and 22 down-regulated) in both of the docetaxel-resistant MCF-7 and MDA-MB-231 cell lines. By 
performing complete-linkage clustering with these consistently SDE lncRNAs, the 12 samples (3 samples for each 
of the 4 cell lines) perfectly clustered into two groups: the parental and resistant groups (Fig. 2D). A compari-
son of the clustering results with a similar number of SDE mRNAs (Fig. 1C) suggested that lncRNAs might be 
more specific biomarkers for distinguishing docetaxel-resistant cells from the non-resistant cells than mRNAs. 
Furthermore, this highlighted the potential application of lncRNAs as predictive biomarkers and for the predic-
tion of response to chemotherapy.
lncRNAs have been described to exert their biological functions by regulating the generation and expression 
of target mRNAs8. Co-expression network analyses have been widely used to predict the target mRNAs of lncR-
NAs by detecting their similar expression patterns15,16, and thus, the WGCNA R software package was used in 
our study to decipher the relationship between the SDE mRNAs and the SDE lncRNAs. By using a hierarchical 
clustering method, we identified 4 groups of co-expressed lncRNAs and mRNAs, termed ‘modules’. Among these, 
the modules “Turquoise” and “Gray” were most significantly associated with a docetaxel-resistant status.
In the Turquoise module, which was positively correlated with docetaxel resistance, ABCB1 was identified as 
one of the central and highly connected genes. We found that 39 genes, including 22 coding and 17 non-coding, 
were linked to ABCB1 in this module. In the 22 coding genes linked to ABCB1, we found that many of the 
genes were implicated in drug or chemotherapy resistance. For instance, ABCB4, another ATP-binding cassette 
gene, which was reported to be involved in taxane resistance7, also clustered in this module. ADAM22 was also 
closely linked to ABCB1. This gene has been reported to function as an estrogen receptor-independent medi-
ator of endocrine-resistant breast cancer45. However, it has not previously been linked to docetaxel resistance. 
Similarly, the gene GPNMB was also linked to ABCB1 in the Turquoise module and was up-regulated in all 
the docetaxel-resistant cells. GPNMB has been shown to induce aggressive cellular phenotypes in breast cancer 
and has been identified as a potential therapeutic target for patients with basal-like breast cancer (BLBC) and 
TNBC46,47. The concordant expression of ABCB1 and other potential drug-resistant genes in docetaxel-resistant 
breast cancer cells indicates that besides ABCB1, there are also other genes that may play an important role in the 
generation of docetaxel resistance, and these genes may contribute to docetaxel resistance in a cooperative way 
with ABCB1. Pathway enrichment with the genes in this module highlighted the important roles of the PI3K-Akt 
and ABC transporter signaling pathways.
Moreover, a striking finding here is that many lncRNAs were also co-expressed with ABCB1 and other poten-
tial drug-resistant genes in this module. We identified a list of lncRNAs closely linked to ABCB1 in the Turquoise 
module (Table 2), indicating that some of these lncRNAs may function as regulators of ABCB1 By analyzing the 
genomic location of the lncRNAs linked with ABCB1, we found that several lncRNAs were located at the regions 
overlapping or near the ABCB1 gene locus. The lncRNA NONHSAG048135.2 was identified as an exonic lncRNA 
of ABCB1, whereas NONHSAG048134.2 (termed ABCB1-AS1) and NONHSAG096479.1 (termed ABCB1-AS2) 
were identified as antisense lncRNAs for ABCB1 Another lncRNA, NONHSAG048143.2, was identified as an 
intergenic lincRNA located 480 kb upstream of ABCB1.
lncRNAs are implicated in a wide-spectrum of biological processes at different molecular levels, including epi-
genetic modifications, transcription, and post-transcriptional processing48, and the functions of lncRNAs appears 
to always to be associated with the location of the lncRNA and the nearby mRNA49,50. Antisense lncRNAs have 
been shown to bind to the complementary pre-mRNAs, regulate RNA editing and splicing and, finally, affect 
the expression levels of mRNAs and proteins51,52. For instance, lncRNA ZEB2 NAT (zinc finger e-box binding 
homeobox 2 natural antisense transcript) was reported to bind to the ZEB2 pre-mRNA and obstruct the splicing 
of the Zeb2 5’-UTR, thus up-regulating the expression of the Zeb2 protein52. Antisense lncRNAs have also been 
shown to increase the stability of mRNAs by forming a lncRNA-mRNA duplex and, thereby, up-regulate gene 
expression53,54. Although, the exact functions of the two novel antisense lncRNAs ABCB1-AS1 and ABCB1-AS2 
are still unclear, and further research needs to be performed, our correlation analysis revealed a strong positive 
correlation between the expressions of these antisense lncRNAs and ABCB1 mRNA (Fig. 4B) and raised the pos-
sibility that these lncRNAs may up-regulate the expression of the ABCB1 gene via RNA splicing or stabilization 
mechanisms.
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In addition to the lncRNAs located within the locus of the mRNAs, accumulating evidence suggests that 
lncRNAs located in the regulatory regions are also critical to the regulation of gene expression39,55. Many 
lncRNA transcripts from enhancer regions have been shown to facilitate the transcription of protein-coding 
genes56. For instance, CCAT1-L, which is transcribed from a super-enhancer region 500 kb upstream of the 
MYC (Proto-Oncogene C-Myc) gene, promotes chromatin interactions between MYC and its upstream regula-
tory elements and, thereby, up-regulates MYC transcription57. Recently, a study of lncRNAs in doxorubicin- and 
vincristine-resistant gastric cancer cells also identified an lncRNA, MRUL, which is located 400 kb downstream 
of ABCB1 and promotes the expression of ABCB110. To our knowledge, this is the only lncRNA reported to 
promote ABCB1 expression in chemotherapy-resistant cancer cells. Since this lncRNA has not been recorded in 
the NONCODE 2016 database, we analyzed the differential expression of the transcripts of MRUL between the 
parental MCF-7 and MDA-MB-231 cells and their docetaxel-resistant sublines. We found that MRUL was dra-
matically up-regulated in the docetaxel-resistant MCF-7 subline compared to the parental MCF-7 cells. However, 
this up-regulation was not apparent in the docetaxel-resistant MDA-MB-231 subline (Fig. 4D). This finding sug-
gested that MRUL may also contribute to docetaxel resistance in ER (estrogen receptor) positive breast cancer but 
maybe not in the TNBC type.
Most intriguingly, in our study, we also identified the lncRNA NONHSAG048143.2 located 480 kb upstream 
of ABCB1. The correlation analysis revealed a strong positive correlation between the expression of this lncRNA 
and ABCB1 mRNA (Fig. 4B), suggesting that this lncRNA may be another enhancer lncRNA for ABCB1. The 
histone H3K4me1/H3K4me3 ratio has been used to characterize enhancer elements across the genome25,58,59. 
Therefore, we downloaded the ChIP-seq datasets of the MCF-7 and MDA-MB-231 breast cancer cells to calculate 
the H3K4me1/H3K4me3 ratios at the TSS of the lncRNA NONHSAG048143.2. Our result revealed that lncRNA 
NONHSAG048143.2 was located in a region presenting an enhancer-like chromatin state (H3K4me1/H3K4me3 
ratio > 1.2) in both the MCF-7 and MDA-MB-231 cells (Fig. 4C). This result strongly suggested that this lncRNA 
might function as an enhancer lncRNA in the up-regulation of the ABCB1 gene in docetaxel-resistant breast 
cancer cells.
In the Gray module, which was negatively correlated with the docetaxel-resistant status, we found that the gene 
TSPYL5 was dramatically and consistently down-regulated in the docetaxel-resistant MCF-7 and MDA-MB-231 
cells. This gene has been involved in the modulation of cell growth and the cellular response to gamma radiation 
probably via the regulation of the Akt signaling pathway60. The overexpression of TSPYL5 has also been linked 
to chemotherapy sensitivity in both lung and prostate cancer cells20,61. The dramatic down-regulation of TSPYL5 
in the docetaxel-resistant breast cancer cells may be involved in the loss of docetaxel sensitivity. Interestingly, we 
found that the lncRNA EPB41L4A-AS2 was expressed in all the parental breast cancer cell lines but was absent in 
all the docetaxel-resistant descendants (Fig. 5C). According to a recent study, this lncRNA may inhibit tumor cell 
proliferation and is associated with favorable prognoses in breast cancer24. However, the role of EPB41L4A-AS2 
in chemotherapy-resistant cancer has not been deciphered yet. Here, we report, for the first time, the deple-
tion of EPB41L4A-AS2 in docetaxel-resistant breast cancer cells. Our correlation analysis also showed that the 
decreased level of EPB41L4A-AS2 in the docetaxel-resistant breast cancer cells was significantly associated with 
an increased level of ABCB1 mRNA (Fig. 5B). These results strongly indicate that the depletion of EPB41L4A-AS2 
contributes to the docetaxel-resistant phenotype in breast cancer cells. In support of this notion, our analysis in 
clinical breast cancers tissues (GSE21997) before neoadjuvant chemotherapy (doxorubicin or docetaxel) also 
showed that the expression of EPB41L4A-AS2 was significantly lower in the patients resistant to neo-adjuvant 
chemotherapy than in non-resistant patients (Fig. 5D).
In conclusion, we performed a comprehensive Illumina-based RNA sequencing and analysis on two 
docetaxel-resistant breast cancer cell lines and their parental breast cancer cell lines. In addition to the most 
studied docetaxel-resistant gene, ABCB1, we also identified other SDE protein-coding genes and pathways, 
which might contribute to the generation of docetaxel resistance. These findings improved our understanding 
of the mechanism underlying docetaxel resistance in breast cancer and suggest that a number of lncRNAs are 
promising candidates as predictive biomarkers for the docetaxel response. To our knowledge, this is the first 
study to report on a global profile of mRNAs and lncRNAs in docetaxel-resistant breast cancer. We identified 
groups of lncRNAs, which were consistently up-regulated or down-regulated in both the docetaxel-resistant 
MCF-7 and MDA-MB-231 cell lines and constructed a co-expression network to decipher the potential regula-
tory relationship between the SDE lncRNAs and mRNAs. Our results highlighted four overexpressed lncRNAs 
that overlapped or were near the ABCB1 locus, which might up-regulate the expression of ABCB1 via different 
mechanisms. We also identified lncRNA EPB41L4A-AS2 as a potential biomarker for docetaxel sensitivity in clin-
ical breast cancer samples. Although further basic biological and clinical research still needs to be performed to 
explore the exact biological function of these newly identified lncRNAs, our study provided potential biomarkers 
to predict the response to docetaxel in breast cancer patients and might help improve the strategy for the treat-
ment of advanced breast cancer.
Methods
Cell culture and treatment. The two human breast cancer cell lines MDA-MB-231 and MCF-7 and their 
docetaxel-resistant sublines MDA-RES and MCF7-RES were obtained from Hansen et al.’s study4.
The MCF-7 cells were cultured in DMEM (Gibco, Thermo Fisher Scientific, USA) plus 1% non-essential 
amino acids (Gibco, Thermo Fisher Scientific, USA) and 5% fetal calf serum (FCS) (Gibco, Thermo Fisher 
Scientific, USA). The MDA-MB-231 cells were cultured in DMEM plus 10% FCS. The culture medium for the 
MDA-RES and MCF7-RES cells was the same as their parental cells except for the supplementation of 65 or 
150 nM of docetaxel (Sanofi Aventis, France), respectively. All the cell lines were grown in 5% carbon dioxide at 
37 °C.
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Total RNA purification and rRNA depletion transcriptome Sequencing. For the Illumina-based 
RNA-Seq, the total RNA from 3 passages of MCF-7, MCF7-RES, MDA-MB-231 and MDA-RES, was purified 
with RNAiso Plus Kit (TAKARA, Japan). After the RNA purification and DNase I digestion, rRNAs were removed 
from the total RNA with RiboMinus Eukaryote Kit (Qiagen, USA). The remained RNAs were fragmented using 
Ambion Fragmentation Solution (Thermo Fisher Scientific, USA). Then the mRNA fragments were used to 
synthesize cDNAs, followed by end repairing and adenine connection. Sequencing adaptors were ligated the 
fragments. Suitable fragments were selected according to the agarose gel electrophoresis results for PCR ampli-
fication. The StepOnePlus System (Applied Biosystems, Thermo Fisher Scientific, USA) and the Agilent 2100 
Bioanaylzer (Agilent Technologies, USA) were used to quantify and qualify the sample libraries in the QC steps. 
Finally, all the libraries were sequenced by the HiSeq. 2000 sequencer (Illumina, USA).
lncRNA and mRNA expression profiling. Firstly, adaptor sequences were removed from the raw reads. 
And low quality reads, which contained more than 50% of low quality bases (base quality < 10) and 5% of unde-
fined nucleotides [N] on the read, were also removed. To avoid the reads mapped to the remaining rRNAs dis-
turbing the next analysis, we aligned the reads to the human ribosomal RNA sequences (rRNA) and filtered out 
the perfect mapping reads. After the above two-step filtering, the remaining reads were considered clean reads 
and were used in next expression profile. In the mRNA analysis, the clean reads were mapped to the human ref-
erence genome (hg19) by TopHat262. Then, the genes annotated in RefSeq were quantified by Cufflinks tools63. 
For lncRNA, the clean reads were mapped to the noncoding RNA transcriptome (NONCODE 201664) by STAR65 
and quantified by RSEM66. The parameters used in the analysis tools referred to the ENCODE RNA-seq data 
processing pipelines (https://www.encodeproject.org/pipelines/). Finally, we obtained all the mRNA and lncRNA 
expression tables represented in both the FPKM and read-count format.
Identification of significantly differentially expressed lncRNAs and mRNAs. The differentially 
expressed lncRNAs and mRNAs between the parental and docetaxel-resistant cells groups were calculated by 
DESeq.67 in the two cell lines, respectively. To ensure that the denominator was not zero when performing the 
division operation, we added 1 to every element in the read-count matrix. The P-value was calculated based on a 
negative binomial distribution model, and adjusted by Benjamini-Hochberg mothed. The criteria of |Log2FC| > 1, 
FDR < 0.1 was used to select the significantly differentially expressed lncRNAs and mRNAs.
GO and KEGG pathway enrichment. Functional annotation enrichment analyses for GO and the KEGG 
pathway were performed using the KOBAS server68. P-value is calculated by hypergeometric test. The Q-value is 
the P-value corrected by Benjamini-Hochberg mothed. The GO terms and pathways with a Q value less than 0.05 
were considered significantly enriched.
Co-expression network analysis. The WGCNA R package18 was used to construct the co-expression net-
work between the significantly differentially expressed lncRNAs and mRNAs.
By hierarchical clustering of the expression data, several modules, which are clusters of highly interconnected 
genes, were identified in the co-expression network. Then, we related the drug-resistant feature to the module 
eigengene to identify the drug-resistant modules (Pearson correlation test, P-value < 0.05). In the drug-resistant 
modules, hub genes were selected by |MM| > 0.8 and |GS| > 0.4, and they were highly connected with other genes. 
The connections among the hub genes were visualized as an unsigned network by Cytoscape69.
Classification of lncRNAs near ABCB1 with the downloaded ChIP-seq (H3K4me1/H3K4me3) 
data. We downloaded the ChIP-seq datasets for the MCF-7 and MDA-MB-231 breast cancer cells from the 
GEO and ENCODE website. The NCBI (National Center for Biotechnology Information) accession number for 
the MDA-MB-231 cell ChIPseq data is GSE49651. The ENCODE accessions for the MCF-7 cell datasets are 
ENCSR493NBY and ENCSR985MIB. Then, we calculated the H3K4me1/H3K4me3 ratio at each TSS (mean over 
interval, 1 kb up and down TSS).
Validation of the SDE mRNAs and lncRNAs. The PCR primers for the eight selected mRNAs (includ-
ing ABCB1, ABCB4, ADAM22, COL21A1, GPNMB, ITGB4, and EPB41L4A) and the five lncRNAs (including 
EPB41L4A-AS2, NONHSAG096479.1, NONHSAG048134.2, NONHSAG048135.2, and NONHSAG048143.2) 
were designed using Primer 5.0 (Sup Table 6). The PCR primers for GAPDH was also designed to serve as the 
endogenous control. The length of the PCR products ranged from 100 bp to 400 bp (Sup Table 6). Total RNAs 
from each cell line was extracted using RNAiso Plus (TAKARA, Japan), and examined Qubit fluorometer 
(Invitrogen, Thermo Fisher Scientific, USA). QPCR was performed in triplicate on an StepOnePlus instrument 
(Applied Biosystems, Thermo Fisher Scientific, USA) using the SYBR Premix Ex Taq II (TAKARA, Japan) rea-
gent. ROX dye II was applied for baseline correction. The relative expressions of the mRNA and lncRNAs were 
calculated with the 2−ΔΔCt method.
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